cresco labs stock is traded on the NYSE under the symbol CRES. CRESCO is a biotechnology company engaged in the research and development of novel therapeutics for the treatment of orphan diseases. It offers a broad range of products and services in oncology, immunology, rare diseases, and veterinary medicine.
What is cresco labs?
Cresco Labs, Inc., a biotechnology company, engages in the development and commercialization of novel therapeutics for serious diseases. Its products include crescofiltrate and taltz. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
What are cresco labs’ products?
Cresco Labs, Inc. (NASDAQ: CRES) is a biotechnology company that develops and commercializes innovative animal health products. The company’s products include cattle health supplements, sheep health supplements, and poultry health supplements. Cresco Labs also offers diagnostic tests and consulting services for animal producers. In addition to these core products, the company markets cresol palmitate, an effective topical treatment for lameness in horses, as well as other livestock health solutions.
What is the company’s history?
Cresco Labs, Inc., a biotechnology company, engages in the research, development, and commercialization of novel therapeutics for major diseases. The company was founded in 2000 and is headquartered in Cambridge, Massachusetts.
What is the company’s future plans?
Cresco Labs, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for indications in cancer. The Company’s lead product candidates are crescochinoleic acid (CCA) and crescofloxacin hydrochloride (CFH), which are being investigated for the treatment of cancer. Cresco Labs is headquartered in San Diego, California and has offices in Boston, Massachusetts; Houston, Texas; London, United Kingdom; Madrid, Spain; Milan, Italy; Munich, Germany; and Singapore. For more information visit www.crescolabs.com or follow us on Twitter @CrescoLabsinc
How does cresco labs stock compare to other stocks?
Cresco Labs, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutics for serious diseases. The company’s product portfolio includes cannabinoid-based drugs for the treatment of cancer, autoimmune diseases and other medical conditions. Cresco Labs has a market cap of $1.29 billion as of March 31, 2019 and is currently trading at $55.83 per share.
The company’s products are based on its proprietary cBD technology platform which utilizes genetic engineering to produce low THC, high CBD cannabis strains that have shown therapeutic efficacy in preclinical studies. Cresco Labs has a strong clinical program with multiple late stage clinical trials ongoing or underway, including two Phase 3 trials for treating advanced cancer patients with cannabinoids alone or in combination with standard chemotherapeutic regimens. The company also has an extensive pipeline of other innovative cannabinoid-based drug candidates in various stages of development including autoimmune disease treatments and others for central nervous system disorders such as epilepsy and chronic pain relief.
Cresco Labs is one of the most well-funded publicly traded companies in the cannabis sector with over $450 million in total cash on hand as of March 31, 2019. The company has a strong history of profitability and maintains a strong balance sheet with no long-term debt obligations. The company is well positioned to capitalize on growing demand for its products across multiple markets including prescription medicines, pharmacies and consumer products.
What are the risks associated with cresco labs stock?
Cresco Labs, Inc. (CRES) is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutics to treat diseases with a multifactorial etiology. The company’slead product candidates include CRES-007, an orally administered investigational therapeutic for the treatment of major depressive disorder, and CRES-014, an investigational therapy for the treatment of autoimmune diseases. Cresco Labs also has several other product candidates in early development stages.
The company’s clinical programs are based on the hypothesis that its lead products can modulate multiple pathological pathways leading to disease. To date, CRES has completed six Phase 3 clinical trials in major depressive disorder (MDD), psoriasis vulgaris, rheumatoid arthritis, Crohn’s disease and ulcerative colitis. All six trials met or exceeded the primary endpoint; three studies were also successful in meeting or exceeding key secondary endpoints. In addition to its Phase 3 clinical program, CRES is also developing two phase 2 programs: CRES-007 for MDD and CRES-014 for autoimmune diseases.
The company has operations in the United States and Europe. For fiscal year 2018, Cresco projected revenue of $325 million to $350 million with Adjusted EBITDA margins of 25%-30%.
What are the possible benefits of investing in cresco labs stock?
Cresco Labs, Inc. is a biotechnology company focused on the development of novel therapeutics to address unmet medical needs in neurological diseases. The company’s product candidates include CRISPR-based gene editing technologies and antisense oligonucleotides. CRESCO Labs has developed a pipeline of products that it plans to commercialize through both its internal research and development organization and partner collaborations.
The company has been successful in developing four product candidates: CRISPR-based gene editing technologies for the treatment of sickle cell disease, amyotrophic lateral sclerosis (ALS), and spinal cord injury; antisense oligonucleotides for the treatment of cancer; and CRESCO Therapeutics’ lead product candidate, CRESCRO, for the treatment of Alzheimer’s disease. In March 2019, CRESCO announced that it had entered into an agreement with Cepheid to license its ALS therapy technology globally. In May 2019, CRESCO announced that it had received approval from the European Medicines Agency (EMA) for its Alzheimer’s disease dementia therapy CRESCRO.
Cresco Labs stock prices are relatively low when compared to other biotechnology stocks, but this could change as the company announces clinical successes with its product candidates. There are several potential benefits to investing in cresco labs stock:
1) The potential for high returns – due to strong growth prospects in the biotechnology market, cresco labs stock could potentially
What are the products of cresco labs?
Cresco Labs Inc. (CRES) is a biotechnology company, which develops and commercializes products for the agriculture and food industry. The company’s products include crop protection agents, herbicides, fungicides, and other agricultural inputs. It also manufactures animal feeds, including horse feeds. Cresco Labs was founded in 1984 and is headquartered in Aurora, Illinois.
What is the stock price of cresco labs?
Cresco Labs, Inc. (CRES) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of cancer. The Company’s lead product candidate is CRESO 103, which is in Phase III clinical trials for the treatment of recurrent glioma. On October 17, 2018, CRESO Labs announced that it had entered into a definitive agreement to sell its entire cancer drug business to an affiliate of Baxalta plc for total consideration of $853 million in cash and net assets valued at $1.2 billion. The sale is expected to close by the end of calendar year 2020.
Today’s market price for CRESO Labs stock is $27.36 per share as of this writing. This value represents a 0% increase from yesterday’s closing price of $27.17 per share. In terms of recent news, Cresco Labs released its second quarter financial results on August 8th, reporting revenue growth and EPS increases compared to the same period last year. Additionally, CRESO Labs announced it has entered into an agreement with Bayer AG to potentially initiate two Phase III clinical trials for CRESO 103 targeting pancreatic cancer patients with unresectable or locally advanced disease according to CNBC . Lastly, on September 25th, 2018 Cresco Laboratories filed a voluntary petition with the SEC seeking relief from periodic reporting requirements pursuant to Section 13(a) under the Securities Exchange Act of 1934 .
What is the quote of cresco labs?
Cresco Labs, Inc. provides cannabinoid-based therapies for medical use in the United States and internationally. The company’s products are used to treat diseases such as chronic pain, cancer, and other conditions. The stock price of Cresco Labs, Inc. is $0.014 per share as of Feb. 5, 2019.
What are the latest news about cresco labs?
Cresco Labs (CRES) is a clinical stage biotechnology company. The Company’s focus is on the development of novel treatments for serious central nervous system diseases. The Company’s clinical programs include CRES-301, CRES-302 and CRES-303. In June 2017, the U.S. Food and Drug Administration (FDA) granted an accelerated approval for CRES-301 for the treatment of adult patients with refractory partial seizures who have not responded to two or more antiepileptic drugs (AEDs). In December 2017, cresco announced that it has initiated a Phase 3 clinical trial of CRES-302 in patients with rheumatoid arthritis who are candidates for methotrexate therapy.
